Wall Street analysts forecast that Roivant Sciences Ltd (NASDAQ:ROIV) will announce $10.13 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Roivant Sciences’ earnings, with the lowest sales estimate coming in at $6.00 million and the highest estimate coming in at $14.27 million. The company is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Roivant Sciences will report full-year sales of $36.99 million for the current financial year, with estimates ranging from $31.70 million to $50.54 million. For the next fiscal year, analysts forecast that the firm will post sales of $44.88 million, with estimates ranging from $8.40 million to $92.11 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Roivant Sciences.
Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Monday, November 15th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.19. The firm had revenue of $13.99 million during the quarter, compared to analyst estimates of $5.30 million.
ROIV stock opened at $7.95 on Friday. Roivant Sciences has a one year low of $5.80 and a one year high of $16.76. The stock has a fifty day moving average price of $9.93.
Roivant Sciences Company Profile
Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.
Recommended Story: Tariff
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.